The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease

被引:26
|
作者
Moss, M. Elizabeth [1 ,2 ]
Carvajal, Brigett [1 ,2 ]
Jaffe, Iris Z. [1 ,2 ]
机构
[1] Tufts Med Ctr, Mol Cardiol Res Inst, 800 Washington Ave,Box 80, Boston, MA 02111 USA
[2] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA
基金
美国国家卫生研究院;
关键词
Endothelial cell; Mineralocorticoid receptor; Cardiovascular disease; Sex differences; Aldosterone; Estrogen; SELECTIVE ALDOSTERONE BLOCKER; EPITHELIAL SODIUM-CHANNEL; RESISTANT HYPERTENSION FOCUS; PRESERVED EJECTION FRACTION; POLYCYSTIC-OVARY-SYNDROME; INDUCED OXIDATIVE STRESS; INTIMA-MEDIA THICKNESS; HEART-FAILURE; DIASTOLIC DYSFUNCTION; BLOOD-PRESSURE;
D O I
10.1016/j.pharmthera.2019.06.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiovascular disease remains the leading cause of death for both men and women. The observation that premenopausal women are protected from cardiovascular disease relative to age-matched men, and that this protection is lost with menopause, has led to extensive study of the role of sex steroid hormones in the pathogenesis of cardiovascular disease. However, the molecular basis for sex differences in cardiovascular disease is still not fully understood, limiting the ability to tailor therapies to male and female patients. Therefore, there is a growing need to investigate molecular pathways outside of traditional sex hormone signaling to fully understand sex differences in cardiovascular disease. Emerging evidence points to the mineralocorticoid receptor (MR), a steroid hormone receptor activated by the adrenal hormone aldosterone, as one such mediator of cardiovascular disease risk, potentially serving as a sex-dependent link between cardiovascular risk factors and disease. Enhanced activation of the MR by aldosterone is associated with increased risk of cardiovascular disease. Emerging evidence implicates the MR specifically within the endothelial cells lining the blood vessels in mediating some of the sex differences observed in cardiovascular pathology. This review summarizes the available clinical and preclinical literature concerning the role of the MR in the pathophysiology of endothelial dysfunction, hypertension, atherosclerosis, and heart failure, with a special emphasis on sex differences in the role of endothelial-specific MR in these pathologies. The available data regarding the molecular mechanisms by which endothelial-specific MR may contribute to sex differences in cardiovascular disease is also summarized. A paradigm emerges from synthesis of the literature in which endothelial-specific MR regulates vascular function in a sex-dependent manner in response to cardiovascular risk factors to contribute to disease. Limitations in this field include the relative paucity of women in clinical trials and, until recently, the nearly exclusive use of male animals in preclinical investigations. Enhanced understanding of the sex-specific roles of endothelial MR could lead to novel mechanistic insights underlying sex differences in cardiovascular disease incidence and outcomes and could identify additional therapeutic targets to effectively treat cardiovascular disease in men and women. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage
    Verdugo, Fernando J.
    Montellano, Felipe A.
    Carreno, Juan E.
    Marusic, Elisa T.
    REVISTA MEDICA DE CHILE, 2014, 142 (01) : 61 - 71
  • [22] Dietary sodium restriction sex specifically impairs endothelial function via mineralocorticoid receptor-dependent reduction in NO bioavailability in Balb/C mice
    Faulkner, Jessica L.
    Harwood, Daisy
    Kennard, Simone
    Antonova, Galina
    Clere, Nicolas
    de Chantemele, Eric J. Belin
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2021, 320 (01): : H211 - H220
  • [23] Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
    Yoshida, Hiroshi
    Rosano, Giuseppe
    Shimizu, Mitsuyuki
    Mochizuki, Seibu
    Yoshimura, Michihiro
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (11) : 1090 - 1094
  • [24] Sex Differences in Kidney Health and Disease
    Harvey, Brian J.
    de la Rosa, Diego Alvarez
    NEPHRON, 2025, 149 (02) : 77 - 103
  • [25] Pharmacology of Aldosterone and the Effects of Mineralocorticoid Receptor Blockade on Cardiovascular Systems
    Yagi, Shusuke
    Akaike, Masashi
    Aihara, Ken-ichi
    Fukuda, Daiju
    Ishida, Masayoshi
    Ise, Takayuki
    Niki, Toshiyuki
    Sumitomo-Ueda, Yuka
    Yamaguchi, Koji
    Iwase, Takashi
    Taketani, Yoshio
    Yamada, Hirotsugu
    Soeki, Takeshi
    Wakatsuki, Tetsuzo
    Shimabukuro, Michio
    Sata, Masataka
    ACTA CARDIOLOGICA SINICA, 2013, 29 (03) : 201 - 207
  • [26] Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease
    Pitt, B
    Stier, CT
    Rajagopalan, S
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2003, 4 (03) : 164 - 168
  • [27] Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
    Kintscher, Ulrich
    Bakris, George L.
    Kolkhof, Peter
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (13) : 3220 - 3234
  • [28] The mineralocorticoid receptor in skin disease
    Perez, Paloma
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (13) : 3178 - 3189
  • [29] Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging
    Gorini, Stefania
    Kim, Seung Kyum
    Infante, Marco
    Mammi, Caterina
    La Vignera, Sandro
    Fabbri, Andrea
    Jaffe, Iris Z.
    Caprio, Massimiliano
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [30] Aldosterone, Mineralocorticoid Receptor Activation, and Cardiovascular Remodeling
    Leopold, Jane A.
    CIRCULATION, 2011, 124 (18) : E466 - E468